Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.

J Pediatr Endocrinol Metab 2008 Jan;21(1):63-72

Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Background: Cyclic intravenous pamidronate treatment is widely used for symptomatic therapy of osteogenesis imperfecta (OI). However, data after discontinuation are very limited.

Aim: The results of cyclical pamidronate treatment in 14 patients with moderate/severe OI and follow up of six of them after discontinuation are presented to assess the effects of pamidronate and its discontinuation.

Patients And Methods: Pamidronate was administered at a dosage of 0.5 mg/kg for 3 successive days every 2 months in 14 patients with OI aged 5.10 +/- 3.68 years. Treatment was stopped in six patients after a duration of 16.33 +/- 4.63 months, due to stable bone mineral density (BMD) values and/or no fracture in the last 6 months, or due to family demand. The main outcome measures were areal BMD (aBMD) of the lumbar spine, biochemical markers of bone metabolism, fracture rate, and clinical evaluation.

Results: Areal BMD and aBMD z-scores showed significant improvement during the treatment period. Both serum and bone-specific alkaline phosphatase values were significantly decreased. Fracture rate reduced significantly from 3.5 +/- 1.01 to 0.83 +/- 0.77 fractures/year. Bone pain, which was severe in five patients, disappeared just after the first cycle, and the activity and mobility of patients increased. aBMD and aBMD z-scores were decreased 1.5 years after discontinuation, although not statistically significant. Annual fracture rate increased significantly. Bone pain recurred in four patients. Pamidronate treatment was reinstituted in five of these patients at the end of 1.5 years.

Conclusion: Cyclical pamidronate treatment is very effective in children with moderate/severe OI. This treatment should be started early enough before the occurrence of irreversible deformities and must be given for a longer time during the growth period.

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem.2008.21.1.63DOI Listing
January 2008
Get 20% Off Journals at LWW.com

Similar Publications

Vitamin D intoxication due to misuse: 5-year experience.

Arch Pediatr 2021 Jan 19. Epub 2021 Jan 19.

Department of Pediatrics, Aksaray University Training and Research Hospital, Aksaray, Turkey.

Introduction: Vitamin D intoxication (VDI) is a well-known cause of hypercalcemia in children and leads to serious kidney, heart, and neurological problems. In the treatment of VDI, the goal is to correct hypercalcemia. Our aim was to evaluate the clinical features of patients with VDI, identify the causes of VDI in our region, and help guide precautions and treatment of VDI. Read More

View Article and Full-Text PDF
January 2021

Severe hypercalcaemia secondary to relapsed Graves' disease.

BMJ Case Rep 2021 Jan 18;14(1). Epub 2021 Jan 18.

Diabetes and Endocrinology, Manchester Royal Infirmary, Manchester, UK.

A 21-year-old woman presented to hospital with abdominal pain and nausea. She had a history of Graves' disease which had been effectively treated with carbimazole for 15 months. Investigations revealed a serum adjusted calcium level of 3. Read More

View Article and Full-Text PDF
January 2021

Bone density, fractures and the associated factors in iranian children and adolescent with Osteogenesis Imperfecta.

BMC Pediatr 2021 Jan 14;21(1):37. Epub 2021 Jan 14.

Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, P.O. Box: 71345-1744, Shiraz, Iran.

Backround: Osteogenesis imperfecta(OI) is a frequent bone fragility disorder in children. The purpose of this study was to assess the BMD and Vitamin D level in children with OI in southern Iran.

Method: This case-control study was conducted on 23 children, clinically diagnosed as osteogenesis imperfecta and 23 age- and gender-matched healthy controls. Read More

View Article and Full-Text PDF
January 2021

Intravenous pamidronate for treatment of osteogenesis imperfecta in Indian children.

Trop Doct 2021 Jan 6:49475520982694. Epub 2021 Jan 6.

Paediatric Orthopaedic Surgeon, Department of Pediatric Orthopedics, Nanavati Hospital, Mumbai, India.

Osteogenesis imperfecta is characterised by low bone mineral density, bone fragility, fractures and deformity. We present five such children treated with intravenous pamidronate, which resulted in a decrease of fracture rate and increase in spinal bone mineral density. Read More

View Article and Full-Text PDF
January 2021

Serum Sp17 Autoantibody Serves as a Potential Specific Biomarker in Patients with SAPHO Syndrome.

J Clin Immunol 2021 Jan 3. Epub 2021 Jan 3.

Department of Immunology, Key Laboratory of T Cell Mediated Cancer Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, State Key Laboratory of Medical Molecular Biology, Peking Union Medical College, Beijing, China.

SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome shows a wide variability in musculoskeletal and cutaneous manifestations, and it is therefore underrecognized and misdiagnosed in the clinic due to a lack of specific markers. In this study, we aimed to identify specific biomarkers by screening serum autoantibodies in SAPHO patients with a 17K human whole-proteome microarray. The serum anti-Sp17 autoantibody was identified and verified to be a specific biomarker in patients with SAPHO syndrome. Read More

View Article and Full-Text PDF
January 2021